DaVita Inc. (NYSE:DVA) Shares Sold by Patton Fund Management Inc.

Patton Fund Management Inc. cut its position in DaVita Inc. (NYSE:DVA) by 13.1% in the fourth quarter, Holdings Channel reports. The firm owned 27,684 shares of the company’s stock after selling 4,188 shares during the period. Patton Fund Management Inc.’s holdings in DaVita were worth $4,140,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its holdings in shares of DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after acquiring an additional 31,502 shares during the period. FMR LLC boosted its stake in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Atom Investors LP purchased a new position in DaVita during the 3rd quarter worth $4,094,000. Assenagon Asset Management S.A. increased its stake in DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock valued at $11,159,000 after purchasing an additional 49,885 shares during the period. Finally, Neo Ivy Capital Management purchased a new position in shares of DaVita during the third quarter worth about $726,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $173.17 on Wednesday. The stock has a market capitalization of $14.20 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 0.82 and a beta of 0.92. The business’s 50 day moving average is $159.01 and its two-hundred day moving average is $154.48. DaVita Inc. has a 12-month low of $105.82 and a 12-month high of $178.75. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.85 earnings per share. Research analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.